Article Sidebar
Published:
Sep 6, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Ginsenoside R3 alleviates non-alcoholic fatty liver disease by regulating the PPARγ/miR-103-3p pathway
Abstract
Purpose: To determine the effect of ginsenoside R3 (Rg3) on non-alcoholic fatty liver disease (NAFLD), and the mechanism involved.
Methods: High-fat diet (HFD) was used to establish an NAFLD mouse model. The mice were daily and intraperitoneally injected with Rg3 at a dose of 1 mg/kg. Blood lipid levels and levels of liver inflammatory markers were measured by enzyme-linked immunosorbent assay (ELISA) while liver pathological changes and lipid accumulation were assessed with hematoxylin-eosin (H&E) staining and oil red O staining, respectively. The mRNA and protein expressions of miR-103-3p and PPARγ were determined with quantitative real-time polymerase chain reaction (qPCR) and western blot assay, respectively. Furthermore, an in vitro hepatocyte NAFLD model was established, and Rg3 was used to treat the cells; PPARγ was overexpressed in the cells. Lipid accumulation, inflammatory factors, as well as PPARγ and miR-103-3p expressions were assessed as indicated for the in vivo studies above. Apoptosis was determined by flow cytometry.
Results: Rg3 alleviated the NAFLD-induced decreases in liver function, reversed NAFLD-mediated pathological injury in liver tissue injury, and decreased hepatic lipid build-up and inflammatory lesions (p < 0.05). It also significantly reversed the upregulation of PPARγ and miR-103-3p in the liver tissue of NAFLD mice. At the cellular level, Rg3 significantly inhibited free fatty acid (FFA)-induced lipid accumulation, apoptosis and inflammatory factors in primary mouse hepatocytes. The PPARγ overexpression counteracted the inhibitory effect of Rg3 on hepatocyte apoptosis, and increased miR103-3p expression (p < 0.05).
Conclusion: These data suggest that Rg3 mitigates NAFLD through regulation of the PPARγ/miR-103- 3p pathway. Therefore, Rg3 may be suitable for the treatment of NAFLD. However, clinical trials are required to ascertain the validity of this therapeutic strategy in clinical practice.
